Business Context and Reporting Period
This Form 8-K filing by Benitec Biopharma Inc. (BNTC) was submitted on September 7, 2022, reporting an event that occurred on September 6, 2022. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory compliance matter regarding the Company's stock listing status.
Material Changes
The material change reported is the receipt of a notification from The Nasdaq Stock Market indicating that the Company failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. Consequently, the Company is currently non-compliant with Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending on March 6, 2023, to regain compliance.
- Regaining Compliance: To cure the deficiency, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days at any time during the 180-day period.
- Secondary Compliance Period: If the Company fails to regain compliance by March 6, 2023, it may be eligible for an additional 180-day period if it meets all other initial listing standards (excluding bid price) and intends to effect a reverse stock split.
- Delisting Risk: If the Company cannot demonstrate compliance or is ineligible for the second period, its securities may be subject to delisting. The Company retains the right to appeal a delisting determination to a Hearings Panel.
- Management Action: Management intends to monitor the closing bid price and may consider implementing available options, such as a reverse stock split, to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of BNTC common stock to assess proximity to the $1.00 threshold.
- Monitor Company announcements regarding the potential implementation of a reverse stock split.
- Track the Company's progress toward the March 6, 2023, deadline for the initial compliance period.
- Review future filings for any updates on the Company's market value of publicly held shares, which is a requirement for the secondary compliance period.